Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Semler Scientific, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation and Allegations - The investigation is prompted by allegations that Semler Scientific may have provided misleading information to investors [1]. - Semler Scientific's stock fell over 9% following the disclosure of initial settlement discussions with the DOJ and the risk of a civil False Claims Act lawsuit [3]. Group 2: Class Action Details - Investors who purchased Semler Scientific securities may be entitled to compensation through a class action without any out-of-pocket fees, facilitated by a contingency fee arrangement [2]. - Interested investors can join the class action by submitting a form or contacting the Rosen Law Firm directly [2]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of Semler Scientific Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1]. Group 1: Company Disclosure - On February 28, 2025, Semler filed its annual report for 2024, indicating a risk of a complaint from the U.S. Department of Justice (DOJ) related to a civil False Claims Act lawsuit [3]. - Semler disclosed receiving an initial civil investigative demand from the DOJ in July 2017 concerning reimbursement claims for its QuantaFlo device [3]. - The company participated in unsuccessful settlement discussions with the DOJ in February 2025 [3]. Group 2: Market Reaction - Following the news of the DOJ investigation, Semler's stock price dropped by $4.03 per share, or 9.4%, closing at $38.89 per share on March 3, 2025 [4].

Core Viewpoint - Semler Scientific Inc. is under investigation for potential violations of federal securities laws and unlawful business practices, particularly concerning its QuantaFlo device reimbursement claims [1][2]. Company Summary - Semler filed its Form 10-K with the SEC on February 28, 2025, revealing an initial civil investigative demand from the U.S. Department of Justice (DOJ) dating back to July 2017 [2]. - The company has faced multiple requests for information from the DOJ, with significant dates including February 2019, December 2021, April 2022, and April 2023 [2]. - Settlement discussions with the DOJ in February 2025 were unsuccessful, leading to concerns that the DOJ may file a civil False Claims Act lawsuit against Semler [2]. - Following the news of the investigation, Semler's share price dropped from $42.92 to $38.89, a decline of $4.03 per share, between February 28 and March 3, 2025 [2]. Legal Context - Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of Semler stockholders regarding the company's legal issues [1]. - The law firm specializes in representing investors in complex litigation, including securities and derivative cases [4].

Core Viewpoint - Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential breaches of fiduciary duty by the Board of Directors and senior management of Semler Scientific Inc. related to securities fraud allegations [1][2]. Investigation Details - The investigation focuses on whether certain officers and/or directors of Semler have engaged in securities fraud [2]. - Semler disclosed in its Form 10-K filed on February 28, 2025, that it received a civil investigative demand from the U.S. Department of Justice (DOJ) in July 2017 regarding claims for reimbursement related to the QuantaFlo device [3]. - Subsequent requests for information from the DOJ occurred in February 2019, December 2021, April 2022, and April 2023, with unsuccessful settlement discussions taking place in February 2025 [3]. - There is a risk that the DOJ may file a complaint in a civil False Claims Act lawsuit seeking damages against Semler [3]. Firm Background - Wolf Haldenstein has extensive experience in prosecuting securities class actions and derivative litigation across state and federal courts [3]. - The firm is recognized for its expertise in shareholder and class litigation, having been appointed to significant positions in complex securities and multi-district litigation by the courts [3].

Company Overview - Semler Scientific, Inc. is a publicly traded company that has adopted Bitcoin as its primary treasury reserve asset and is one of the leading corporate holders of Bitcoin [5] - In May 2024, Semler Scientific became the second U.S. publicly traded company to adopt a Bitcoin treasury strategy, intending to strategically accumulate Bitcoin using proceeds from equity and debt financings, as well as cash flows from operations [5] - The company is also a pioneer in developing and marketing technology products and services for evaluating and treating chronic diseases, with its flagship product, QuantaFlo®, being a rapid point-of-care test for cardiovascular diseases [5] Leadership Changes - Natalie Brunell has been appointed to the board of directors, reflecting Semler Scientific's commitment to its Bitcoin treasury strategy and strengthening its leadership within the Bitcoin community [1][2] - Eric Semler, chairman of Semler Scientific, emphasized that Brunell's insights will be instrumental in pursuing the company's Bitcoin treasury strategy and delivering long-term value to stockholders [2] Natalie Brunell's Background - Natalie Brunell is recognized as a top-rated podcast host and influential educator in the Bitcoin space, hosting the leading Bitcoin podcast 'Coin Stories' [3] - She has a background as an award-winning TV journalist and investigative reporter, holding a regional news Emmy for breaking news coverage and has experience as an adjunct professor [4]

Core Viewpoint - Wolf Haldenstein Adler Freeman & Herz LLP is investigating claims on behalf of investors of Semler Scientific Inc. regarding potential securities fraud by the company and its officers and/or directors [1][2]. Investigation Details - The investigation is focused on whether Semler and certain officers and/or directors have engaged in securities fraud [2]. - Semler disclosed in its Form 10-K filed on February 28, 2025, that it received a civil investigative demand from the U.S. Department of Justice (DOJ) in July 2017 concerning claims for reimbursement related to the QuantaFlo device [3]. - The company has received multiple requests for information from the DOJ over the years, with the most recent being in April 2023 [3]. - In February 2025, Semler engaged in unsuccessful settlement discussions with the DOJ, which raises the risk of a potential civil False Claims Act lawsuit seeking damages [3]. Firm Background - Wolf Haldenstein has extensive experience in prosecuting securities class actions and derivative litigation in various courts across the United States [3]. - The firm is recognized for its expertise in shareholder and class litigation, having been appointed to significant positions in complex securities and multi-district litigation by the courts [3].

Financial Data and Key Metrics Changes - Total revenues in Q1 2025 were $8.8 million, down approximately 44% compared to Q1 2024 [15] - Operating expenses in Q1 2025 were $39.9 million, compared to $8.9 million in Q1 2024, including a $29.8 million contingency reserve related to a DOJ settlement [15] - The net loss for Q1 2025 was $64.7 million, or $6.74 per share, compared to a net income of $6.1 million, or $0.88 per share in Q1 2024 [18] Business Line Data and Key Metrics Changes - The healthcare business is experiencing pressure from payment changes made by CMS, impacting revenue [12] - The company is targeting growth in the cardiovascular space and plans to introduce additional FDA cleared products [12][25] Market Data and Key Metrics Changes - The company has acquired a total of 3,808 Bitcoins valued at approximately $400 million, making it the fourth largest Bitcoin treasury company in the US [6] - In 2025, the company acquired 1,510 Bitcoins with a BTC yield of 22.2%, resulting in a BTC dollar gain of $52 million [6] Company Strategy and Development Direction - The company prioritizes its Bitcoin treasury strategy while managing its healthcare business to generate cash for Bitcoin purchases [10] - The strategic focus includes diversifying the customer base and expanding into new markets with potentially life-saving products [25] Management's Comments on Operating Environment and Future Outlook - Management acknowledges headwinds in the healthcare business but sees opportunities for growth in the cardiovascular space [12] - The company aims to minimize declines in QuantiFlo revenue while maintaining infrastructure for innovation and growth [25] Other Important Information - The company completed a $100 million convertible note financing round, using most proceeds to buy Bitcoin [8] - A new $500 million ATM program became effective on April 22, 2025, to support Bitcoin acquisitions [8][20] Q&A Session Summary Question: What are your plans this year for accumulating more Bitcoin? - The company has ambitious plans to increase its Bitcoin stockpile and is confident in utilizing its $500 million ATM for additional acquisitions [23] Question: What's driving the underlying trends in the business, and what do you expect for 2025? - Despite government payment changes, the company continues to see testing and customer additions, focusing on minimizing revenue declines while expanding its product offerings [24][25]

Financial Data and Key Metrics Changes - Total revenues in Q1 2025 were $8.8 million, down approximately 44% compared to Q1 2024 [15] - Operating expenses in Q1 2025 were $39.9 million, compared to $8.9 million in Q1 2024, including a $29.8 million contingency reserve related to a DOJ settlement [15] - The net loss for Q1 2025 was $64.7 million, or $6.74 per share, compared to a net income of $6.1 million, or $0.88 per share in Q1 2024 [18] Business Line Data and Key Metrics Changes - The healthcare business is experiencing pressure from payment changes made by CMS, impacting revenue [12] - The company is targeting growth in the cardiovascular space and plans to introduce additional FDA cleared products [12][25] Market Data and Key Metrics Changes - The company has acquired a total of 3,808 Bitcoins valued at approximately $400 million, making it the fourth largest Bitcoin treasury company in the US [6] - In 2025, the company acquired 1,510 Bitcoins with a BTC yield of 22.2%, resulting in a BTC dollar gain of $52 million [6] Company Strategy and Development Direction - The company prioritizes its Bitcoin treasury strategy while managing its healthcare business to generate cash for Bitcoin purchases [10] - The strategic focus includes diversifying the customer base and innovating in the healthcare sector [12][25] Management's Comments on Operating Environment and Future Outlook - Management acknowledges headwinds in the healthcare business but sees potential for growth through new initiatives [12] - The company aims to minimize declines in QuantiFlo revenue while expanding into new markets [25] Other Important Information - The company launched a Bitcoin dashboard for investors to track Bitcoin-related statistics [21] - A new $500 million ATM program became effective on April 22, 2025, to support Bitcoin acquisitions [8] Q&A Session Summary Question: What are your plans this year for accumulating more Bitcoin? - The company has ambitious plans to increase its Bitcoin stockpile and is confident in utilizing its $500 million ATM for additional acquisitions [23] Question: What's driving the underlying trends in the business, and what do you expect for 2025? - Despite government payment changes, the company continues to see testing and customer additions, focusing on maintaining infrastructure for growth in cardiovascular disease states [24][25]

Financial Data and Key Metrics Changes - Total revenues in Q1 2025 were $8.8 million, down approximately 44% compared to Q1 2024 [13] - Operating expenses in Q1 2025 were $39.9 million, compared to $8.9 million in Q1 2024, including a $29.8 million contingency reserve related to a DOJ settlement [13] - The net loss for Q1 2025 was $64.7 million, or $6.74 per share, compared to a net income of $6.1 million, or $0.88 per share in Q1 2024 [15] Business Line Data and Key Metrics Changes - The healthcare business is experiencing pressure from payment changes made by CMS, but there are signs of growth in diversifying the customer base and introducing new FDA cleared products [11] - The company is pursuing a new 510(k) clearance for a product extension aimed at diagnosing heart failure, expected in 2025 [11] Market Data and Key Metrics Changes - The company has acquired a total of 3,808 Bitcoins valued at nearly $400 million, making it the fourth largest Bitcoin treasury company in the U.S. [6] - In 2025, the company acquired 1,510 Bitcoins with a yield of 22.2%, resulting in a BTC dollar gain of $52 million [6] Company Strategy and Development Direction - The corporate strategy is focused on three core principles: prioritizing the Bitcoin treasury strategy, ensuring the healthcare business generates cash, and increasing Bitcoin holdings [9] - The company aims to manage its healthcare business to generate cash primarily for Bitcoin purchases [4] Management's Comments on Operating Environment and Future Outlook - Management acknowledges headwinds in the healthcare business but remains optimistic about future growth opportunities in the cardiovascular space [11] - The company emphasizes its commitment to executing its Bitcoin treasury strategy alongside its healthcare business [24] Other Important Information - The company completed a $100 million convertible note financing round, using most proceeds to buy Bitcoin [7] - A new $500 million ATM program became effective on April 22, 2025, to support further Bitcoin acquisitions [7] Q&A Session Summary Question: What are your plans this year for accumulating more Bitcoin? - The company has ambitious plans to increase its Bitcoin stockpile and is confident in utilizing its $500 million ATM for additional acquisitions [21] Question: What's driving the underlying trends in the business, and what do you expect for 2025? - Despite government payment adjustments, the company is focused on minimizing declines in QuantiFlo revenue while expanding its customer base and targeting new markets [22][23]

The Semler Vision: Medical and Monetary Freedom Empowering Early Detection. Backed by Bitcoin. May 13, 2025 Forward-Looking Statements This presentation includes statements that are, or may be deemed, "forward-looking statements." In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believe," "estimate," "anticipate," "expect," "plan," "intend," "may," "could," "might," "will," "should," or, in each case, their negative or other va ...